Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 16Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 9Specimen Handling 8Everolimus 8pembrolizumab 7cabozantinib 6Cisplatin 6fluorodopa F 18 5Etoposide 5trametinib 4surufatinib 4lanreotide 4dabrafenib 4cemiplimab 4X-Rays 4Temozolomide 4Nivolumab 4Lutetium-177 4Lutetium 4Fluorodeoxyglucose F18 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3lenvatinib 3copper dotatate CU-64 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Surveys and Questionnaires 3Somatostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × 68Ga-FAPI × Endocrine × Clear all
NCT07132645 2025-09-23

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡